An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins

International Journal of Oncology

Volumn 32, Issue 4, 2008, Pages 777-789

  Aigner, Maximilian ^a   Janke, Markus ^a   Lulei, Maria ^a   Beckhove, Philipp ^a   Fournier, Philippe ^a   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cancer vaccination; Costimulation; Fusion protein; Immunocytokine

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; HN PROTEIN; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR; TUMOR VACCINE; CANCER VACCINE; INTERLEUKIN 2;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; BYSTANDER EFFECT; CANCER IMMUNIZATION; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME LINKED IMMUNOSPOT ASSAY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; VACCINE PRODUCTION; ANIMAL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; NEWCASTLE DISEASE PARAMYXOVIRUS; T LYMPHOCYTE;

AGED; ANIMALS; ANTIGENS, CD28; ANTIGENS, CD3; CANCER VACCINES; HN PROTEIN; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; MICE; MIDDLE AGED; NEWCASTLE DISEASE VIRUS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 44449123706     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Viola A and Lanzavecchia A: T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104-106, 1996.
2. Wulfing C, Rabinowitz JD, Beeson C, Sjaastad MD, McConnell HM and Davis MM: Kinetics and extent of T cell activation as measured with the calcium signal. J Exp Med 185: 1815-1825, 1997.
3. Viola A, Schroeder S, Sakakibara Y and Lanzavecchia A: T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 283: 680-682, 1999.
4. Tuosto L and Acuto O: CD28 affects the earliest signaling events generated by TCR engagement. Eur J Immunol 28: 2131-2142, 1998.
5. Sharpe AH and Freeman GJ: The B7-CD28 superfamily. Nat Rev Immunol 2: 116-126, 2002.
6. Acuto O and Michel F: CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 3: 939-951, 2003.
7. Iezzi G, Karjalainen K and Lanzavecchia A: The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8: 89-95, 1998.
8. Iezzi G, Scotet E, Scheidegger D and Lanzavecchia A: The interplay between the duration of TCR and cytokine signaling determines T cell polarization. Eur J Immunol 29: 4092-4101, 1999.
9. Schwartz RH: T cell anergy. Annu Rev Immunol 21: 305-334, 2003.
10. Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, Nunez G, Tang A, Sayegh M, Hancock WW, Strom TB; and Turka LA: Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 5: 1303-1307, 1999.
11. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T and Thompson CB: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3: 87-98, 1995.
12. Jenkins MK, Taylor PS, Norton SD and Urdahl KB: CD28 delivers a costimulatory signal involved in antigen- specific IL-2 production by human T cells. J Inummol 147: 2461-2466, 1991.
13. Lenschow DJ, Walunas TL and Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258, 1996.
14. Zambricki E, Shigeoka A, Kishimoto H, Sprent J, Burakoff S, Carpenter C, Milford E and McKay D: Signaling T-cell survival and death by IL-2 and IL-15. Am J Transplant 5: 2623-2631, 2005.
15. Haas C, Lulei M, Fournier P, Arnold A and Schirrmacher V: T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine 23: 2439-2453, 2005.
16. Haas C, Lulci M, Fournier P, Arnold A and Schirrmacher V: A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. Int J Cancer 118: 658-667, 2006.
17. Bian H, Fournier P, Moormann R, Peeters B and Schirrmacher V: Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther 12: 295-303, 2005.
18. Washburn B and Schirrmacher V: Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, cbemokines and finally apoptosis. Int J Oncol 21: 85-93, 2002.
19. Fiola C, Peeters B, Fournier P, Arnold A, Bucur M and Schirrmacher V: Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 119: 328-338, 2006.
20. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R and Ertel C: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6: 63-73, 1999.
21. Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Hacker B, Schumacher M and Schirrmacher V: Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 15: 1354-1366, 1997.
22. Schirrmacher V: Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 54: 587-598, 2005.
23. Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagmuller E, Buchcik R, Nagel M and Saeger HD: Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 2: 21-28, 1996.
24. Schirrmacher V, Ahlert T, Probstle T, Steiner HH, Herold-Mende C, Gerhards R, Hagmuller E and Steiner HH: Immunization with virus-modified tumor cells. Semin Oncol 25: 677-696, 1998.
25. Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y, Helmke BH, Weidauer H, Schirrmacher V and Herold-Mende C: Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 64: 8057-8061, 2004.
26. Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, Schuele-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H, Kiessling M, Kunze S, Schirrmacher V and Herold-Mende C: Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 22: 4272-4281, 2004.
27. Ertel C, Millar NS, Emmerson PT, Schirrmacher V and von Hoegen P: Viral hemagglutinin augments peptide-speeific cytotoxic T cell responses. Eur J Inummol 23: 2592-2596, 1993.
28. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V and Umansky V: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7: 452-458, 2001.
29. Parkinson-Lawrence EJ, Dean CJ, Chang M, Hopwood JJ, Meikle PJ and Brooks DA: Immunochemical analysis of CD107a (LAMP-1). Cell Inummol 236: 161-166, 2005.
30. Ando H, Saio M, Ohe N, Tamakawa N, Yu H, Nakayama T, Yoshimura S, Kaku Y, Iwama T, Shinoda J, Sakai N and Takami T: B7.1 immunogene therapy effectively activates CD(4+) tumor-infiltrating lymphocytes in the central nervous system in comparison with B7.2 gene therapy. Int J Oncol 20: 807-812, 2002.
31. Yang G, Hellstrom KE, Hellstrom I and Chen L: Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/ CTLA-4 costimulatory molecules. J Inummol 154: 2794-2800, 1995.
32. Hoshitani Y, Ishida H, Otsuki N, Shirakawa T, Gotoh A and Nibu K: Induction of immunological antitumor effects by adenovirus-mediated gene transfer of B7-1 in a murine squamous cell carcinoma cell line. Arch Otolaryngol Head Neck Surg 133: 270-275, 2007.
33. Yang Y, Yang S, Ye Z, Jaffar J, Zhou Y, Cutter E, Lieber A, Hellstrom I and Hellstrom KE: Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res 67: 2339-2344, 2007.
34. Takahashi T, Hirano N, Takahashi T, Chiba S, Yazaki Y and Hirai H: Immunogene therapy against mouse leukemia using B7 molecules. Cancer Gene Ther 7: 144-150, 2000.
35. Parney IF, Chang LJ, Farr-Jones MA, Hao C, Smylie M and Petruk KC: Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J Neurooncol 78: 71-80, 2006.
36. Olive D, Cerdan C, Costello R, Sielleur I, Ragueneau M, Pages F, Klasen S, Nunes J and Imbert J: CD28 and CTLA-4 cluster report. In: Leucocyte Typing V - White Cell Differentiation Antigens. Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF and Todd RF (eds). Vol. 1, Oxford University Press, Oxford, pp 360-370, 1995.
37. Sabel MS, Hess SD, Egilmez NK, Conway TF Jr, Chen FA and Bankert RB: CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. Cancer Immunol Immunother 54: 944-952, 2005.
38. Nagamori M, Kawaguchi S, Murakami M, Wada T, Nagoya S, Yamashita T, Inobe M and Uede T: Intrinsic and extrinsic manipulation of B7/CTLA-4 interaction for induction of anti-tumor immunity against osteosarcoma cells. Anticancer Res 22: 3223-3227, 2002.
39. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB and Allison JP: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 94: 8099-8103, 1997.
40. Becker JC, Pancook JD, Gillies SD, Furukawa K and Reisfeld RA: T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183: 2361-2366, 1996.
41. Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X, Lo KM, Lan Y, Super M, Gillies SD and Reisfeld RA: Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 57: 4948-4955, 1997.
42. + memory T cells. Nature 441: 890-893, 2006.
43. Kroon HM, Li Q, Teitz-Tennenbaum S, Whitfield JR, Noone AM and Chang AE: 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members. J Immunother 30: 406-416, 2007.
44. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG and Schlom J: A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 59: 5800-5807, 1999.
45. Hirano N, Takahashi T, Takahashi T, Azuma M, Okumura K, Yazaki Y, Yagita H and Hirai H: Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. Hum Gene Ther 8: 1375-1384, 1997.
46. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153: 421-428, 1994.
47. Rossig C, Pscherer S, Landmeier S, Altvater B, Jurgens, H and Vormoor J: Adoptive cellular immunotherapy with CD19-specific T cells. Klin Padiatr 217: 351-356, 2005.
48. + T cells in an antitumor cell attack. Cancer Res 67: 2265-2273, 2007.
49. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC and Cooper LJ: CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66: 10995-11004, 2006.
50. + T cells to antigen stimulation in vivo. Nat Immunol 1: 47-53, 2000.